07-434
抗-BRCA1抗体
serum, Upstate®
别名:
Anti-PNCA4, Anti-PPP1R53, Anti-BRCAI, Anti-BRCC1, Anti-BROVCA1, Anti-FANCS, Anti-IRIS, Anti-PSCP, Anti-RNF53
产品名称
抗-BRCA1抗体, serum, Upstate®
biological source
rabbit
conjugate
unconjugated
antibody form
serum
antibody product type
primary antibodies
clone
polyclonal
species reactivity
human
manufacturer/tradename
Upstate®
technique(s)
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable
isotype
IgG
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
Quality Level
Gene Information
human ... BRCA1(672)
Analysis Note
对照
阳性抗原对照：货号12-309，HeLa细胞核提取物。加入等体积的Laemmli样品还原性缓冲液至10 μL提取物中，煮沸5分钟以对样品进行还原。在微凝胶每个泳道上样20 μg经还原的提取物。
阳性抗原对照：货号12-309，HeLa细胞核提取物。加入等体积的Laemmli样品还原性缓冲液至10 μL提取物中，煮沸5分钟以对样品进行还原。在微凝胶每个泳道上样20 μg经还原的提取物。
已通过免疫印迹法对HeLa核提取物进行常规评估
Application
用抗BRCA1抗体（兔多克隆抗体）检测BRCA1，已在IHC、IP & WB中起作用。 这种BRCA1抗体已在人类样本中进行了测试。
研究子类别
细胞周期，DNA 复制&修复
细胞周期，DNA 复制&修复
研究类别
表观遗传学&核功能
表观遗传学&核功能
Biochem/physiol Actions
识别人BRCA1。
Disclaimer
除非我们的产品目录或产品附带的其他公司文档另有说明，否则我们的产品仅供研究使用，不得用于任何其他目的，包括但不限于未经授权的商业用途、体外诊断用途、离体或体内治疗用途或任何类型的消费或应用于人类或动物。
General description
220 kDa
已经确定了乳腺癌的两个主要易感基因BRCA1和BRCA2。这两个基因都被认为是肿瘤抑制基因。BRCA1和BRCA2内的突变是大多数家族性乳腺癌病例的原因。BRCA1和BRCA2基因产物的功能分析已经确定了它们在转录调控和DNA损伤修复中的双重参与。 BRCA1通过p53和p21基因影响细胞周期调节，并且由于表达降低而导致的BRCA1功能丧失导致细胞周期停滞。在体内，BRCA1和BRCA2在快速增殖的细胞中以最大水平表达。此特征与BRCA1和BRCA2以细胞周期依赖性方式表达的体外观察结果一致。在乳腺发育过程中，BRCA1和BRCA2的表达在快速增殖的细胞区室中被诱导。
Immunogen
GST标记的融合蛋白对应人BRCA1的1301-1863位氨基酸。
Other Notes
浓度：请参考批次特异性浓缩物的分析证书。
Physical form
含有0.035%叠氮化钠和30％甘油的血清。在-20°C为液体形式。
未纯化
Preparation Note
自收到之日起在-20°C可稳定保存2年。避免反复冻融。为了最大程度地回收产品，在融化后和取下盖子之前，将原始样品瓶进行离心。
Legal Information
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
存储类别
12 - Non Combustible Liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Ligand-dependent differences in estrogen receptor beta-interacting proteins identified in lung adenocarcinoma cells corresponds to estrogenic responses.
Ivanova, M; Abner, S; Pierce, W; Klinge, C
Proteome Science null
BAL1 and its partner E3 ligase, BBAP, link Poly(ADP-ribose) activation, ubiquitylation, and double-strand DNA repair independent of ATM, MDC1, and RNF8.
Yan, Q; Xu, R; Zhu, L; Cheng, X; Wang, Z; Manis, J; Shipp, MA
Molecular and cellular biology null
Aurélia Noll et al.
Cancer cell international, 16, 53-53 (2016-07-05)
Poly(ADP-ribose) polymerase (PARP) inhibitors have entered the clinics for their promising anticancer effect as adjuvant in chemo- and radiotherapy and as single agent on BRCA-mutated tumours. Poly(ADP-ribose) glycohydrolase (PARG) deficiency was also shown to potentiate the cytotoxicity of genotoxic agents
Yifan Wang et al.
The Journal of clinical investigation, 126(8), 3145-3157 (2016-07-28)
Patients with cancers that harbor breast cancer 1 (BRCA1) mutations initially respond well to platinum and poly(ADP-ribose) polymerase inhibitor (PARPi) therapy; however, resistance invariably arises in these patients and is a major clinical problem. The BRCA1185delAG allele is a common
Qingsheng Yan et al.
Molecular cell, 36(1), 110-120 (2009-10-13)
Although the BBAP E3 ligase and its binding partner BAL are overexpressed in chemotherapy-resistant lymphomas, the role of these proteins in DNA damage responses remains undefined. Because BAL proteins modulate promoter-coupled transcription and contain structural motifs associated with chromatin remodeling
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持